HUP0200320A2 - Recombinant virus expressing foreign dna encoding feline cd80, feline ctla-4 or feline cd86 and uses thereof - Google Patents

Recombinant virus expressing foreign dna encoding feline cd80, feline ctla-4 or feline cd86 and uses thereof

Info

Publication number
HUP0200320A2
HUP0200320A2 HU0200320A HUP0200320A HUP0200320A2 HU P0200320 A2 HUP0200320 A2 HU P0200320A2 HU 0200320 A HU0200320 A HU 0200320A HU P0200320 A HUP0200320 A HU P0200320A HU P0200320 A2 HUP0200320 A2 HU P0200320A2
Authority
HU
Hungary
Prior art keywords
feline
recombinant viruses
ctla
protein
well
Prior art date
Application number
HU0200320A
Other languages
Hungarian (hu)
Inventor
Mark D. Cochran
Barbara J. Winslow
Original Assignee
Schering-Plough Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering-Plough Ltd. filed Critical Schering-Plough Ltd.
Publication of HUP0200320A2 publication Critical patent/HUP0200320A2/en
Publication of HUP0200320A3 publication Critical patent/HUP0200320A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Abstract

A találmány tárgyát rekombináns vírusok képezik, melyek egy vírusgenomjának nem kulcsfontosságú régiójába inszertálva legalább egy -proteint kódoló - idegen nukleinsavat tartalmaznak, mely protein akövetkezők bármelyike: a macskaeredetű CD28-, CD80-, CD86- vagy CTLA-4-protein vagy ezek valamely immunogén része. A találmány szerintirekombináns vírusok a fenti idegen nukleinsavakon kívül promótertés/vagy detektálható markergént és/vagy patogén organizmusból származóimmunogént kódoló nukleinsavat is tartalmazhatnak. A találmány tárgyátképezik továbbá a találmány szerinti rekombináns vírusok immunizálásszempontjából hatásos mennyiségét tartalmazó vakcinák, valamint atalálmány szerinti rekombináns vírusok alkalmazása macskafélékimmunrendszerének serkentésére. A találmány szerinti rekombinánsvírusok és az azokat tartalmazó vakcinák alkalmasak macskafélékfertőző betegségek elleni vakcinálásra, továbbá macskafélék fertőzőbetegségeinek, valamint neopláziás, degeneratív, autoimmun ésimmunhiányos állapotainak kezelésére. ÓThe subject of the invention is recombinant viruses which, when inserted into a non-key region of a viral genome, contain at least one foreign nucleic acid encoding a protein, which protein is any of the following: the feline CD28, CD80, CD86 or CTLA-4 protein or an immunogenic part thereof . In addition to the above foreign nucleic acids, the recombinant viruses according to the invention may also contain nucleic acids encoding a promoter and/or a detectable marker gene and/or an immunogen from a pathogenic organism. The invention also covers vaccines containing an effective amount of the recombinant viruses according to the invention from the point of view of immunization, as well as the use of the recombinant viruses according to the invention to stimulate the immune system of cats. The recombinant viruses according to the invention and the vaccines containing them are suitable for vaccination against feline infectious diseases, as well as for the treatment of feline infectious diseases as well as neoplastic, degenerative, autoimmune and immunodeficiency conditions. HE

HU0200320A 1998-05-01 1999-04-30 Recombinant virus expressing foreign dna encoding feline cd80, feline ctla-4 or feline cd86 and uses thereof HUP0200320A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7171198A 1998-05-01 1998-05-01

Publications (2)

Publication Number Publication Date
HUP0200320A2 true HUP0200320A2 (en) 2002-05-29
HUP0200320A3 HUP0200320A3 (en) 2006-03-28

Family

ID=22103082

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0200320A HUP0200320A3 (en) 1998-05-01 1999-04-30 Recombinant virus expressing foreign dna encoding feline cd80, feline ctla-4 or feline cd86 and uses thereof

Country Status (20)

Country Link
EP (1) EP1073759B1 (en)
JP (2) JP2002513581A (en)
KR (1) KR100796799B1 (en)
AT (1) ATE511545T1 (en)
AU (1) AU761755B2 (en)
BR (1) BR9915970A (en)
CA (1) CA2327528C (en)
CZ (1) CZ20003934A3 (en)
ES (1) ES2367245T3 (en)
HK (1) HK1032606A1 (en)
HU (1) HUP0200320A3 (en)
IL (2) IL139372A0 (en)
NO (1) NO20005482L (en)
NZ (1) NZ507793A (en)
PL (1) PL199359B1 (en)
RU (1) RU2244006C2 (en)
SK (1) SK16162000A3 (en)
UA (1) UA73718C2 (en)
WO (1) WO1999057295A1 (en)
ZA (1) ZA200006124B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7078512B2 (en) 1998-05-01 2006-07-18 Schering-Plough Animal Health Corporation Nucleic acid encoding feline CD86
WO2001024764A2 (en) * 1999-10-06 2001-04-12 The Trustees Of The University Of Pennsylvania Cell targeting compositions and methods of using the same
WO2006094665A1 (en) 2005-03-08 2006-09-14 Kenton Srl Chimeric recombinant antigens of toxoplasma gondii
GB201601498D0 (en) 2016-01-27 2016-03-09 Pirbright Inst The Coronavirus
US11013798B2 (en) 2016-03-21 2021-05-25 South Dakota Board Of Regents Orf virus-based platform for vaccine delivery

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1001032A3 (en) * 1989-08-18 2005-02-23 Chiron Corporation Recombinant retroviruses delivering vector constructs to target cells
ATE226257T1 (en) * 1992-06-26 2002-11-15 Akzo Nobel Nv RECOMBINANT FELINE HERPES VIRUS VACCINE
DE69332480T2 (en) * 1992-07-30 2003-07-17 Akzo Nobel Nv VACCINE VECTORS FROM RECOMBINANT CAT HERPESVIRUS
US6084067A (en) * 1993-07-26 2000-07-04 Dana-Farber Cancer Institute CTLA4/CD28 ligands and uses therefor
TW377373B (en) * 1993-09-22 1999-12-21 Wyeth Corp Recombinant raccoon pox viruses and their use as an effective vaccine against feline infectious peritonitis virus disease
EP1016418B1 (en) * 1994-10-03 2009-12-30 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Host cell comprising a recombinant virus expressing an antigen and a recombinant virus expressing an immunostimulatory molecule
US6221361B1 (en) * 1995-01-19 2001-04-24 Syntro Corporation Recombinant swinepox virus
US5820869A (en) * 1995-06-07 1998-10-13 American Home Products Corporation Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection

Also Published As

Publication number Publication date
KR20010085242A (en) 2001-09-07
NO20005482D0 (en) 2000-10-31
NO20005482L (en) 2000-12-27
AU3968899A (en) 1999-11-23
EP1073759B1 (en) 2011-06-01
CA2327528A1 (en) 1999-11-11
EP1073759A1 (en) 2001-02-07
KR100796799B1 (en) 2008-01-22
WO1999057295A1 (en) 1999-11-11
RU2244006C2 (en) 2005-01-10
ES2367245T3 (en) 2011-10-31
NZ507793A (en) 2003-05-30
JP2009178163A (en) 2009-08-13
ES2367245T8 (en) 2011-12-09
HUP0200320A3 (en) 2006-03-28
CA2327528C (en) 2010-10-12
IL139372A (en) 2010-11-30
PL346012A1 (en) 2002-01-14
ZA200006124B (en) 2002-04-02
PL199359B1 (en) 2008-09-30
CZ20003934A3 (en) 2001-09-12
UA73718C2 (en) 2005-09-15
SK16162000A3 (en) 2001-12-03
BR9915970A (en) 2001-12-04
JP2002513581A (en) 2002-05-14
HK1032606A1 (en) 2001-07-27
AU761755B2 (en) 2003-06-12
ATE511545T1 (en) 2011-06-15
IL139372A0 (en) 2001-11-25

Similar Documents

Publication Publication Date Title
ATE419368T1 (en) SYSTEM FOR TRANSFER AND EXPRESSION OF HETEROLOGUE GENES INTO THE BONE MARCH IN VIVO
DE69737886D1 (en) INFECTIOUSE RNA VIRUS CLONE, VACCINE, AND THEREFORE DERIVED DIAGNOSTIC ASSAYS
EP0879284A4 (en) Gene expression vectors which generate an antigen specific immune response and methods of using the same
WO2001039797A3 (en) Artificial chromosome constructs containing nucleic acid sequences capable of directing the formation of a recombinant rna-virus
WO1997048370A3 (en) Vaccines comprising synthetic genes
WO2002022686A3 (en) Defensin-antigen fusion proteins
DE69732029D1 (en) DNA-Containing VACCINES
EP0538299A1 (en) Equine herpesvirus-4 tk?- vaccine
HUP0200320A2 (en) Recombinant virus expressing foreign dna encoding feline cd80, feline ctla-4 or feline cd86 and uses thereof
HUP9901005A2 (en) Glycoprotein b of the rfhv/kshv subfamily of herpes viruses
DE60117053D1 (en) PREPARATION OF RECOMBINANT ARTIFICIAL YEAST CHROMOSOME CONTAINING THE GENOME OF HUMAN CYTOMEGALOVIRUS
WO2002022687A3 (en) Viral chemokine-tumur antigen fusion proteins
EP0432220A4 (en) Vaccines and diagnostic assays for haemophilus influenzae
DE69332264D1 (en) MUTANTS OF THE INFECTIOUS CATTLE RHINOTRACHEITIS VIRUS AND VACCINE
FR2635532B1 (en) HYBRID RECOMBINANT HBSAG PARTICLES: MORPHOLOGICAL CHARACTERISTICS OF THE HBSAG ANTIGEN CONTAINING 1 IMMUNOGENIC SEQUENCE INDUCING NEUTRALIZING ANTIBODIES DIRECTED AGAINST HIV OR LIKELY TO BE RECOGNIZED BY SUCH ANTIBODIES; NUCLEOTIDE SEQUENCES ENCODING FOR SUCH PARTICLES; VACCINES CONTAINING THEM
WO1996040764A3 (en) Nucleotide and amino acid sequences of hypervariable region 1 of the envelope 2 gene of hepatitis c virus
AU686000B2 (en) Infectious peritonitis vaccine
WO2001007625A3 (en) Ehrlichia canis genes and vaccines
BR9910153A (en) nucleic acid and polypeptides from feline cd80, feline cd80, feline cd28 and feline ctla-4
WO2000049166A3 (en) Production of helper dependent adenovirus vectors based on use of endonucleases
HUP0103871A2 (en) Recombinent celo virus and celo virus dna
Morgan et al. Recombinant vaccine against Marek's disease
HK1002983A1 (en) Diagnostic and therapeutic system
CN115838762A (en) CCHFV recombinant eukaryotic expression vector pVAX1-CCHFV-Gc, construction method and application
Kooi et al. Are differences in biological properties of MHV associated with differences in specific regions of their nucleocapsid mRNA?

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: SCHERING-PLOUGH LTD., CH

Free format text: FORMER OWNER(S): SCHERING-PLOUGH LTD., CH

Owner name: THE TEXAS A&M UNIVERSITY SYSTEM, US

Free format text: FORMER OWNER(S): SCHERING-PLOUGH LTD., CH

FD9A Lapse of provisional protection due to non-payment of fees